^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PF-06688992

    i
    Other names: PF-06688992, PF 06688992, GD3 ADC
    Associations

    News

    Trials
    Company:
    Pfizer
    Drug class:
    GD3-targeted antibody-drug conjugate
    Associations

    News

    Trials
    6years
    Pfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma (clinicaltrials.gov)
    P1, N=7, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | Trial completion date: May 2020 --> Jan 2020 | Trial primary completion date: May 2020 --> Jan 2020
    Clinical • Trial completion • Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600 • BRAF V600K
    |
    PF-06688992